LTS:0A45 (USA)
Business Description
Moderna Inc
NAICS : 325412
SIC : 2836
200 Technology Square, Cambridge, MA, USA, 02139
Compare
Compare
Traded in other countries / regions
MRNA.Austria
•
M1RN34.Brazil
•
0QF.Germany
•
MRNA.Mexico
•
MRNA.Peru
•
0A45.UK
•
MRNA.USA
Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.9 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | 744.86 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 8.61 | |||||
Beneish M-Score | 0.48 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 200.9 | |||||
3-Year Book Growth Rate | 96.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Industry Rank | -31.31 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 23.73 | |||||
9-Day RSI | 34.04 | |||||
14-Day RSI | 40.5 | |||||
6-1 Month Momentum % | 13.17 | |||||
12-1 Month Momentum % | -56.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.99 | |||||
Quick Ratio | 1.71 | |||||
Cash Ratio | 1.16 | |||||
Days Inventory | 123.91 | |||||
Days Sales Outstanding | 46.52 | |||||
Days Payable | 15.17 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 81.73 | |||||
Operating Margin % | 70.19 | |||||
Net Margin % | 63.07 | |||||
ROE % | 106.42 | |||||
ROA % | 60.9 | |||||
ROIC % | 89.85 | |||||
ROC (Joel Greenblatt) % | 1273.21 | |||||
ROCE % | 109.81 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 4.46 | |||||
Forward PE Ratio | 6.56 | |||||
PE Ratio without NRI | 4.82 | |||||
Price-to-Owner-Earnings | 7.15 | |||||
PS Ratio | 2.81 | |||||
PB Ratio | 3.18 | |||||
Price-to-Tangible-Book | 3.2 | |||||
Price-to-Free-Cash-Flow | 6.83 | |||||
Price-to-Operating-Cash-Flow | 6.51 | |||||
EV-to-EBIT | 3.19 | |||||
EV-to-Forward-EBIT | 4.16 | |||||
EV-to-EBITDA | 3.13 | |||||
EV-to-Forward-EBITDA | 4.09 | |||||
EV-to-Revenue | 2.25 | |||||
EV-to-Forward-Revenue | 2.37 | |||||
EV-to-FCF | 5.95 | |||||
Price-to-Graham-Number | 0.8 | |||||
Price-to-Net-Current-Asset-Value | 10.45 | |||||
Earnings Yield (Greenblatt) % | 31.31 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 22,284 | ||
EPS (TTM) ($) | 32.81 | ||
Beta | 0 | ||
Volatility % | 53.62 | ||
14-Day RSI | 40.5 | ||
14-Day ATR ($) | 9.830124 | ||
20-Day SMA ($) | 169.2355 | ||
12-1 Month Momentum % | -56.58 | ||
52-Week Range ($) | 115.61 - 464.61 | ||
Shares Outstanding (Mil) | 391.2 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Moderna Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |